Allogeneic bone marrow transplantation for leukemia following piperazinedione and fractionated total body irradiation

✍ Scribed by Meletios A. Dimopoulos; Dr. Jonathan C. Yau; Susan D. Huan; Sundar Jagannath; Gary Spitzer; Jorge A. Spinolo; Gunar K. Zagars; Charles F. Lemaistre; Karel A. Dicke; Axel R. Zander

• Publisher: John Wiley and Sons
• Year: 1994
• Tongue: English
• Weight: 404 KB
• Volume: 46
• Category: Article
• ISSN: 0361-8609
• DOI: 10.1002/ajh.2830460205

✦ Synopsis

Between 1980 and 1988,126 patients with leukemia were treated with piperazinedione and fractionated total body irradiation (TBI) followed by allogeneic bone marrow transplantation from HLA matched siblings. Sixty-one patients had acute myelogenous leukemia, 46 acute lymphoblastic leukemia, and 19 chronic myelogenous leukemia. Patients with acute leukemia in first complete remission were transplanted only if perceived to have a low probability of remaining in remission with conventional therapy. The toxicity from the preparative regimen was similar to that of cyclophosphamide and TBI except that none of the patients in the study had hemorrhagic cystitis or veno-occlusive disease. After a median follow up of 114 months, 29 patients (23%) are still alive without relapse. The survival of patients with acute myelogenous or lymphoblastic leukemia transplanted in their first remission were 35% and 43%, respectively. The survival of patients transplanted in their first chronic phase of chronic myelogenous leukemia was 60%. The results of this preparative regimen are comparable to those of cyclophosphamide and TBI.